TARS logo

Tarsus Pharmaceuticals (TARS) EBIT

annual EBIT:

-$108.11M+$24.56M(+18.51%)
December 31, 2024

Summary

  • As of today (July 1, 2025), TARS annual earnings before interest & taxes is -$108.11 million, with the most recent change of +$24.56 million (+18.51%) on December 31, 2024.
  • During the last 3 years, TARS annual EBIT has fallen by -$94.33 million (-684.98%).
  • TARS annual EBIT is now -7907.93% below its all-time high of -$1.35 million, reached on December 31, 2018.

Performance

TARS EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSincome statement metrics

quarterly EBIT:

-$23.05M-$2.11M(-10.06%)
March 31, 2025

Summary

  • As of today (July 1, 2025), TARS quarterly earnings before interest & taxes is -$23.05 million, with the most recent change of -$2.11 million (-10.06%) on March 31, 2025.
  • Over the past year, TARS quarterly EBIT has increased by +$11.74 million (+33.74%).
  • TARS quarterly EBIT is now -315.10% below its all-time high of $10.71 million, reached on March 31, 2021.

Performance

TARS quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSincome statement metrics

TTM EBIT:

-$96.37M+$11.74M(+10.86%)
March 31, 2025

Summary

  • As of today (July 1, 2025), TARS TTM earnings before interest & taxes is -$96.37 million, with the most recent change of +$11.74 million (+10.86%) on March 31, 2025.
  • Over the past year, TARS TTM EBIT has increased by +$48.31 million (+33.39%).
  • TARS TTM EBIT is now -15124.49% below its all-time high of -$633.00 thousand, reached on September 30, 2019.

Performance

TARS TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

TARS EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+18.5%+33.7%+33.4%
3 y3 years-685.0%-15.7%-121.7%
5 y5 years-2415.3%-988.1%-1257.7%

TARS EBIT Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-685.0%+18.5%-343.3%+43.7%-72.2%+33.7%
5 y5-year-2415.3%+18.5%-315.1%+43.7%-2560.7%+33.7%
alltimeall time-7907.9%+18.5%-315.1%+43.7%<-9999.0%+33.7%

TARS EBIT History

DateAnnualQuarterlyTTM
Mar 2025
-
-$23.05M(+10.1%)
-$96.37M(-10.9%)
Dec 2024
-$108.11M(-18.5%)
-$20.94M(-0.8%)
-$108.11M(-15.6%)
Sep 2024
-
-$21.10M(-32.5%)
-$128.11M(-11.8%)
Jun 2024
-
-$31.28M(-10.1%)
-$145.33M(+0.4%)
Mar 2024
-
-$34.78M(-15.0%)
-$144.69M(+9.1%)
Dec 2023
-$132.67M(+121.0%)
-$40.94M(+6.8%)
-$132.67M(+26.8%)
Sep 2023
-
-$38.32M(+25.1%)
-$104.66M(+18.6%)
Jun 2023
-
-$30.64M(+34.6%)
-$88.27M(+40.5%)
Mar 2023
-
-$22.76M(+76.0%)
-$62.83M(+4.7%)
Dec 2022
-$60.03M
-$12.94M(-41.0%)
-$59.99M(-3.0%)
Sep 2022
-
-$21.93M(+321.8%)
-$61.85M(+10.5%)
Jun 2022
-
-$5.20M(-73.9%)
-$55.95M(+28.7%)
DateAnnualQuarterlyTTM
Mar 2022
-
-$19.92M(+34.6%)
-$43.47M(+238.6%)
Dec 2021
-$13.77M(-49.0%)
-$14.80M(-7.7%)
-$12.84M(+34.9%)
Sep 2021
-
-$16.04M(-320.2%)
-$9.52M(+162.8%)
Jun 2021
-
$7.28M(-32.0%)
-$3.62M(-74.4%)
Mar 2021
-
$10.71M(-193.4%)
-$14.17M(-47.5%)
Dec 2020
-$27.00M(+528.2%)
-$11.48M(+13.2%)
-$27.00M(+62.6%)
Sep 2020
-
-$10.14M(+210.8%)
-$16.61M(+134.0%)
Jun 2020
-
-$3.26M(+54.1%)
-$7.10M(+85.1%)
Mar 2020
-
-$2.12M(+95.4%)
-$3.83M(+123.4%)
Dec 2019
-$4.30M(+218.4%)
-$1.08M(+71.2%)
-$1.72M(+171.2%)
Sep 2019
-
-$633.00K
-$633.00K
Dec 2018
-$1.35M
-
-

FAQ

  • What is Tarsus Pharmaceuticals annual earnings before interest & taxes?
  • What is the all time high annual EBIT for Tarsus Pharmaceuticals?
  • What is Tarsus Pharmaceuticals annual EBIT year-on-year change?
  • What is Tarsus Pharmaceuticals quarterly earnings before interest & taxes?
  • What is the all time high quarterly EBIT for Tarsus Pharmaceuticals?
  • What is Tarsus Pharmaceuticals quarterly EBIT year-on-year change?
  • What is Tarsus Pharmaceuticals TTM earnings before interest & taxes?
  • What is the all time high TTM EBIT for Tarsus Pharmaceuticals?
  • What is Tarsus Pharmaceuticals TTM EBIT year-on-year change?

What is Tarsus Pharmaceuticals annual earnings before interest & taxes?

The current annual EBIT of TARS is -$108.11M

What is the all time high annual EBIT for Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals all-time high annual earnings before interest & taxes is -$1.35M

What is Tarsus Pharmaceuticals annual EBIT year-on-year change?

Over the past year, TARS annual earnings before interest & taxes has changed by +$24.56M (+18.51%)

What is Tarsus Pharmaceuticals quarterly earnings before interest & taxes?

The current quarterly EBIT of TARS is -$23.05M

What is the all time high quarterly EBIT for Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals all-time high quarterly earnings before interest & taxes is $10.71M

What is Tarsus Pharmaceuticals quarterly EBIT year-on-year change?

Over the past year, TARS quarterly earnings before interest & taxes has changed by +$11.74M (+33.74%)

What is Tarsus Pharmaceuticals TTM earnings before interest & taxes?

The current TTM EBIT of TARS is -$96.37M

What is the all time high TTM EBIT for Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals all-time high TTM earnings before interest & taxes is -$633.00K

What is Tarsus Pharmaceuticals TTM EBIT year-on-year change?

Over the past year, TARS TTM earnings before interest & taxes has changed by +$48.31M (+33.39%)
On this page